TRIUMF inks deal for actinium-225 production

2018 12 11 00 02 7009 Atom Nuclear Lab 400

Canadian particle accelerator center TRIUMF has entered a collaboration with Fusion Pharmaceuticals for the production of actinium-225, which has potential as a cancer-killing radioisotope.

Under the deal, Fusion will provide a financial investment that will enable TRIUMF to upgrade its production infrastructure for actinium-225. In return, Fusion will gain preferred access to actinium-225, an alpha-emitting isotope with a short half-life that can be combined with a molecular agent to target cancer cells.

Fusion is developing a line of targeted alpha therapies based on actinium-225 for radiation therapy applications.

Page 1 of 435
Next Page